Aeterna Zentaris (AEZS - Free Report) closed at $3.67 in the latest trading session, marking a -0.54% move from the prior day. This move was narrower than the S&P 500's daily loss of 2.33%. Elsewhere, the Dow lost 2.24%, while the tech-heavy Nasdaq lost 3.05%.
Coming into today, shares of the drug developer had gained 73.24% in the past month. In that same time, the Medical sector gained 1.22%, while the S&P 500 lost 1.93%.
AEZS will be looking to display strength as it nears its next earnings release, which is expected to be March 27, 2019. In that report, analysts expect AEZS to post earnings of -$0.13 per share. This would mark year-over-year growth of 45.83%. Our most recent consensus estimate is calling for quarterly revenue of $1.21 million, up 572.22% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $0.44 per share and revenue of $26.70 million, which would represent changes of +132.59% and +2792.77%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for AEZS. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 780% higher within the past month. AEZS is currently sporting a Zacks Rank of #1 (Strong Buy).
Valuation is also important, so investors should note that AEZS has a Forward P/E ratio of 8.39 right now. This represents a discount compared to its industry's average Forward P/E of 23.14.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 70, putting it in the top 27% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.